|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US7662365||REDHILL||Polymer conjugates of opioid antagonists|| |
(11 months ago)
|US7786133||REDHILL||Chemically modified small molecules|| |
(4 years from now)
|US9012469||REDHILL||Crystalline naloxol-peg conjugate|| |
(8 years from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8617530||REDHILL||Polymer conjugates of opioid antagonists|| |
(11 months ago)
|US7056500||REDHILL||Polymer conjugates of opioid antagonists|| |
(8 months from now)
|US8067431||REDHILL||Chemically modified small molecules|| |
(1 year, 2 months from now)
Movantik is owned by Redhill.
Movantik contains Naloxegol Oxalate.
Movantik has a total of 6 drug patents out of which 2 drug patents have expired.
Expired drug patents of Movantik are:
Movantik was authorised for market use on 16 September, 2014.
Movantik is available in tablet;oral dosage forms.
Movantik can be used as treatment of opioid-induced constipation.
The generics of Movantik are possible to be released after 02 April, 2032.
Market Authorisation Date: 16 September, 2014
Treatment: Treatment of opioid-induced constipation
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic